Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Core Insights - Sera Prognostics Inc. will report its fourth quarter and full year 2024 financial results on March 19, 2025, after market close, followed by a conference call to discuss operational highlights and financial results [1] - The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information [1][3] - Sera Prognostics is dedicated to providing early pregnancy information to reduce healthcare delivery costs and has a robust pipeline of diagnostic tests [3] Company Overview - Sera Prognostics is a leading health diagnostics company headquartered in Salt Lake City, Utah, specializing in precision pregnancy care [3] - The company's mission is to enhance the health of mothers and newborns, particularly through the PreTRM® Test, which predicts the risk of spontaneous premature delivery [3][5] - The PreTRM® Test is the only broadly validated blood-based biomarker test for early risk prediction of preterm birth in asymptomatic singleton pregnancies [5] Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last five years [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]